Search Results

Return to List
Results 1–18 of 18
Title Date
1.

Brand Versus Generic Oral Contraceptives

Number 375

(Reaffirmed 2013)

ABSTRACT:The U.S. Food and Drug Administration considers generic and brand name oral contraceptive (OC) products clinically equivalent and interchangeable. The American College of Obstetricians and Gynecologists supports patient or clinician requests for branded OCs or continuation of the same gen...

August 2007

PDF Format
2.

Aromatase Inhibitors in Gynecologic Practice

Number 412

(Reaffirmed 2012)

ABSTRACT: Aromatase inhibitors appear to be effective as an adjuvant treatment for early-stage and late-stage breast cancer. Their role in chemoprevention of breast cancer in high-risk patients remains to be defined. Side effects of aromatase inhibitors in postmenopausal women are due to estrogen-...

August 2008

PDF Format
3.

Misoprostol for Postabortion Care

Number 427

ABSTRACT: The World Health Organization estimates that 67,000 women, mostly in developing countries, die each year from untreated or inadequately treated abortion complications. Postabortion care, a term commonly used by the international reproductive health community, refers to a specific set of ...

February 2009

PDF Format
4.

Compounded Bioidentical Menopausal Hormone Therapy

Number 532

(Reaffirmed 2014, Replaces No. 387, November 2007 and No. 322, November 2005)

ABSTRACT: Although improvement in long-term health is no longer an indication for menopausal hormone therapy, evidence supporting fewer adverse events in younger women, combined with its high overall effectiveness, has reinforced its usefulness for short-term treatment of menopausal symptoms. Meno...

August 2012

PDF Format
5.

Risk of Venous Thromboembolism Among Users of Drospirenone-Containing Oral Contraceptive Pills

Number 540

ABSTRACT: Although the risk of venous thromboembolism is increased among oral contraceptive users compared with nonusers who are not pregnant and not taking hormones, and some data have suggested that use of drospirenone-containing pills has a higher risk of venous thromboembolism, this risk is st...

November 2012

PDF Format
6.

Access to Emergency Contraception

Number 542

ABSTRACT: Emergency contraception includes contraceptive methods used to prevent pregnancy in the first few days after unprotected intercourse, sexual assault, or contraceptive failure. Although the U.S. Food and Drug Administration approved the first dedicated product for emergency contraception ...

November 2012

PDF Format
7.

Over-the-Counter Access to Oral Contraceptives

Number 544

ABSTRACT: Unintended pregnancy remains a major public health problem in the United States. Access and cost issues are common reasons why women either do not use contraception or have gaps in use. A potential way to improve contraceptive access and use, and possibly decrease unintended pregnancy ra...

December 2012

PDF Format
8.

Postmenopausal Estrogen Therapy: Route of Administration and Risk of Venous Thromboembolism

Number 556

ABSTRACT: The development of menopausal symptoms and related disorders, which lead women to seek prescriptions for postmenopausal estrogen therapy and hormone therapy, is a common reason for a patient to visit her gynecologist, but these therapies are associated with an increased risk of venous th...

April 2013

PDF Format
9.

Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women

Number 557

ABSTRACT: Initial evaluation of the patient with acute abnormal uterine bleeding should include a prompt assessment for signs of hypovolemia and potential hemodynamic instability. After initial assessment and stabilization, the etiologies of acute abnormal uterine bleeding should be classified usi...

April 2013

PDF Format
10.

Integrating Immunizations Into Practice

Number 558

ABSTRACT: Given demonstrated vaccine efficacy, safety, and the large potential for prevention of many infectious diseases among adults, newborns, and pregnant women, obstetrician–gynecologists should embrace immunizations as an integral part of their women’s health care practice. To provide direct...

April 2013

PDF Format
11.

Ethical Issues With Vaccination for the Obstetrician–Gynecologist

Number 564

ABSTRACT: Because of the growing importance of infectious disease prevention in the individual patient and the larger community, it is vital that Fellows of the American College of Obstetricians and Gynecologists be prepared to navigate the practical and ethical challenges that come with vaccinati...

May 2013

PDF Format
12.

Solutions for Surgical Preparation of the Vagina

Number 571

ABSTRACT: Currently, only povidone-iodine preparations are approved for vaginal surgical-site antisepsis. However, there are compelling reasons to consider chlorhexidine gluconate solutions for off-label use in surgical preparation of the vagina, especially in women with allergies to iodine. Altho...

September 2013

PDF Format
13.

Preexposure Prophylaxis for the Prevention of Human Immunodeficiency Virus

Number 595

Abstract: Preexposure prophylaxis is defined as the administration of antiretroviral medications to individuals who are not infected with human immunodeficiency virus (HIV) and are at the highest risk of acquiring HIV infection. In combination with other proven HIV-prevention methods, preexposure ...

May 2014

PDF Format
14.

Tamoxifen and Uterine Cancer

Number 601

(Replaces Committee Opinion Number 336, June 2006)

ABSTRACT: Tamoxifen, a nonsteroidal antiestrogen agent, is widely used as adjunctive therapy for women with breast cancer, and it has been approved by the U.S. Food and Drug Administration for adjuvant treatment of breast cancer, treatment of metastatic breast cancer, and reduction in breast cance...

June 2014

PDF Format
15.

OnabotulinumtoxinA and the Bladder

Number 604

ABSTRACT: In January 2013, the U.S. Food and Drug Administration approved the use of onabotulinumtoxinA (also known as Botox A) for the treatment of overactive bladder, thus providing another treatment option for women. Symptoms of overactive bladder have been shown to significantly improve after ...

June 2014

PDF Format
16.

Primary Ovarian Insufficiency in Adolescents and Young Women

Number 605

ABSTRACT: Primary ovarian insufficiency is the depletion or dysfunction of ovarian follicles with cessation of menses before age 40 years. There is no consensus on criteria to identify primary ovarian insufficiency in adolescents, and delay in diagnosis is common. Health care providers who make th...

July 2014

PDF Format
17.

Options for Prevention and Management of Heavy Menstrual Bleeding in Adolescent Patients Undergoing

Number 606

ABSTRACT: Adolescents undergoing cancer treatment are at high risk of heavy menstrual bleeding, and gynecologists may be consulted either before the initiation of cancer treatment to request strategies for menstrual suppression or during an episode of severe heavy bleeding to stop the bleeding eme...

August 2014

PDF Format
18.

Chronic Antithrombotic Therapy and Gynecologic Surgery

Number 610

ABSTRACT: Surgery can present a management dilemma for gynecologists whose patients receive chronic antithrombotic therapy because the risk of hemorrhagic complications must be balanced against the risk of thromboembolic complications. Interruption of antithrombotic therapy to reduce perioperative...

October 2014

PDF Format